VR Logo

Kodiak Sciences Inc (KOD) download report


Healthcare | Biotechnology & Pharma Research

Kodiak Sciences Inc (KOD) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases.

IPO Date: 04-Oct-2018

Co-Founder, Chairman, CEO & Pres: Dr. Victor Perlroth M.D.

Sr. VP, CFO & Sec.: Mr. John A. Borgeson CPA, M.B.A., MBA, CPA

Listing: NASDAQ: KOD

Country: United States

Headquarters: Palo Alto, CA

Website: https://kodiak.com

Key Facts

Market cap: $402.64 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-312.25 Mln

Cash: $671.73 Mln

Total Debt: $81.40 Mln

Insider's Holding: 7.91%

Liquidity: Low

52 Week range: $4.90 - 131.97

Shares outstanding: 51,953,600

6 Years Aggregate:

  • CFO: $-367.58 Mln
  • EBITDA: $-507.29 Mln
  • Net Profit: $-533.96 Mln

Stock Performance

Time Period Kodiak Sciences (KOD) S&P BSE Sensex S&P Small-Cap 600
YTD-90.86-9.18-18.78
1 month11.99-4.78-8.00
3 months0.39-9.66-13.65
1 Year-91.670.81-17.19
3 Years-12.8310.336.10
5 Years--11.345.87
10 Years--11.749.84
As on 01-Jul-2022
Year Kodiak Sciences (KOD) S&P Small-Cap 600 S&P BSE Sensex
2021-42.2925.2721.99
2020104.189.5715.75
2019913.3820.8614.38